Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female subjects aged 18-65 years
Subjects with relapsing remitting MS defined by 2010 revised McDonald criteria
Patients with Expanded Disability Status Scale (EDSS) score of 0-6.5
Interferon-beta (IFN-β) treatment for at least 18 months.
Positive IFN-NAb titer at screening or within 6 months prior to screening
Patients with disease activity despite treatment with IFN-ß measured by gadolinium-enhancing lesions on T1-weighted images on MRI using a triple-dose gadolinium protocol and/or new or newly enlarging T2 lesions (T2 lesions: compared to a reference MRI performed within the last 18 months)
You may not be if
patients with previous or current disease of immune system
active infections
cardiovascular risk patients
Patients unable to undergo MRI scans, including claustrophobia or history of hypersensitivity to gadolinium-DTPA
Clareo Health | ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon
